Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

active_not_recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_2

Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D

NCT06649266
completedphase_2

A Study of RBD1016 in CHB Participants

NCT05961098
completedphase_1

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

NCT05017116
completedphase_1

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

NCT04685564

Clinical Trials (4)

Showing 4 of 4 trials
NCT06649266Phase 2

Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D

Active Not Recruiting
NCT05961098Phase 2

A Study of RBD1016 in CHB Participants

Completed
NCT05017116Phase 1

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

Completed
NCT04685564Phase 1

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4